Meet our team
We are building a precision metabolic oncology company focused on pancreatic ductal adenocarcinoma (PDAC). Our team approach prioritises mechanistic rigour, biomarker-defined development, and milestone discipline.
Leadership
Profiles will expand as Mito Laboratories builds its scientific and operational team.
Joshua Owide
Founder
Joshua (“Josh”) Owide holds a BSc in Physiology and Pharmacology and has worked for over 20 years as a pharmaceutical industry analyst, with commentary featured across a range of media outlets. He has also contributed as an author to industry publications, including Deloitte’s Return on Pharmaceutical Innovation.
He founded Mito Laboratories to translate mitochondrial and metabolic biology into a disciplined, biomarker-defined therapeutic strategy in pancreatic cancer, with a focus on synthetic metabolic lethality and apoptosis activation under metabolic stress.
Advisors
Mito Laboratories is assembling an advisory group spanning translational oncology, mitochondrial metabolism, medicinal chemistry, and regulatory strategy. Advisors will be listed here once confirmed and permissioned.
Translational Oncology
Clinical and preclinical expertise in pancreatic cancer model selection, biomarkers, and trial endpoints.
Medicinal Chemistry
Hit-to-lead strategy and optimisation across LDH, PDK1, and BH3-mimetic modalities.
Regulatory & Development
IND-enabling planning, toxicology strategy, and combination development considerations.
Join the mission
If you are a scientist, clinician, or operator interested in metabolic oncology and pancreatic cancer, we welcome introductions.